Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trinity Biotech ( (TRIB) ) has shared an update.
At the Annual General Meeting on September 30, 2025, Trinity Biotech’s shareholders approved amendments to the company’s Constitution, which were subsequently disclosed. Additionally, the company and its subsidiaries amended their credit agreement with Perceptive Credit Holdings III, L.P., reflecting a strategic financial adjustment. These changes are indicative of Trinity Biotech’s efforts to refine its corporate governance and financial strategies, potentially impacting its operational flexibility and stakeholder relations.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, high debt levels, and negative equity. Technical indicators also suggest a bearish trend, further weighing down the score. The negative P/E ratio and lack of dividend yield highlight valuation concerns. These factors collectively indicate significant risks and challenges for the company.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech is a public limited company based in Bray, Co. Wicklow, Ireland, operating in the pharmaceutical and diagnostic sector. The company is involved in the research, manufacturing, and distribution of pharmaceutical, medicinal, and diagnostic products and services.
Average Trading Volume: 4,373,211
Technical Sentiment Signal: Sell
Current Market Cap: $17.33M
For an in-depth examination of TRIB stock, go to TipRanks’ Overview page.